Acute myeloïde leukemie (AML)
EORTC1301: InDACtion vs. induction: 10-day decitabine versus conventional chemotherapy (3+7) followed by allografting in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
Chronische myeloïde leukemie (CML)
Muscle function: The relation between muscle function and muscle pain in patients with chronic myeloid leukemia (CML): a pilot study
CMyLife effectmeting: The impact of CMyLife on quality of life, information supply, patient empowerment and guideline and medication adherence in patients with CML
Zorgpad analyse CML: Pathways of care that lead to a sustained and deep treatment response in chronic myeloid leukemia
Chronische lymfatische leukemie (CLL)
HOVON 140: A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (Rve) versus obinutuzumab (GA101) plus venetoclax (Gve) versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without del (17P) or TP53 mutation
Myelodysplastisch syndroom (MDS)
EU-MDS: A prospective, multicentre European registry for newly diagnosed patients with myelodysplastic syndromes (MDS), including acute myeloid leukaemia with 20-30 percent marrow blasts (former RAEB-t), and chronic myelomonocytic leukaemia (CMML)
Myeloproliferatieve neoplasieën (MPN)
HOVON 134: A phase II trial in patients with myelofibrosis (primary, post-ET or post-PV-MF) treated with the selective JAK2 inhibitor pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation
Non-Hodgkin lymfomen (NHL)
HOVON 119: Efficacy of alternating immunochemotherapy consisting of R-CHOP + RHAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma
HOVON 127: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
HOVON 133 / TRIANGLE: Autologous transplantation after a rituximab/ibrutinib/ara-c containing induction in generalized mantle cell lymphoma – A randomized European MCL network trial
HOVON 136: Phase I-II study combining brentuximab vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation
HOVON 152: A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements
Multipel myeloom (MM)
HOVON 114: Pomalidomide combined with carfilzomib and dexamethasone (PCd) for induction and consolidation followed by pomalidomide combined with dexamethasone vs pomalidomide maintenance for patients with multiple myeloma in first relapse after prior 1st line treatment with lenalidomide and bortezomib
NivoDara: A phase 2 study of nivolumab combined with daratumumab with or without low-dose cyclophosphamide in relapsed/refractory multiple myeloma
Stamceltransplantatie (SCT)
PSCT19: Vaccination with PD-L1/L2-silenced minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation (a phase I/II study)
Supportive care
ORASTEM: Oral complications in patients treated with hematopoietic stem cell transplantation
AzoR-Man: PCR based detection of azole resistance in A. fumigatus to improve patient outcome. A prospective multicentre intervention study
SPARKLE: Improving sleep quality, psychosocial functioning and cancer related fatigue with light therapy
Transfusiegeneeskunde
PACER: A randomized controlled trial on prophylactic platelet transfusion prior to central venous catheter placement in patients with trombocytopenia
BITE: A nationwide epidemiological and laboratory case cohort study investigating risk factors for bleeding in hemato-oncology patients
Stolling
PRO-RBDD: Prospective data collection on patients with rare bleeding disorders
RBiN: Rare bleeding disorders in the Netherlands
HemoNED: Landelijk register van patiënten met hemofilie en aanverwante aandoeningen
EUHASS: European haemophilia safety surveillance system registry
OPTI-CLOT: Peri-operative pharmacokinetic-guided dosing of clotting factor in hemophilia
DAVID: DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A
Little DAVID: Desmopressin and FVIII concentrate combination treatment in non-severe hemophilia A patients undergoing minor interventions
HiN-6: Haemophilia in the Netherlands 6
Obizur EU PASS: Prospective, non-interventional study to evaluate the safety and effectiveness of Obizur in real-life practice
DYNAMICS: The Dynamic interplay between bleeding phenotype and baseline factor level in moderate and mild hemophilia A and B
PRIDES: Observational study on pregnancy outcome in women with inherited bleeding disorders
Hemoglobinopathie
STARRING: Sickle cell disease: targeting alloantibody formation reduction; risk factors, and genetics
Paroxysmale nachtelijke hemoglobinurie (PNH)
RPNH01: Paroxysmal nocturnal hemoglobinuria (PNH) registry
AK581: Akari long term safety coversin
DAHLIA / ABP959: A randomized, double-blind, active-controlled phase 3 study evaluating the efficacy and safety of ABP 959 compared with eculizumab in adult subjects with paroxysmal nocturnal hemoglobinuria (PNH)
Ga terug naar de algemene homepage Studieinformatie.